NASDAQ:CRIS Curis (CRIS) Stock Price, News & Analysis $1.46 -0.64 (-30.48%) Closing price 04:00 PM EasternExtended Trading$1.49 +0.03 (+1.78%) As of 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Curis Stock (NASDAQ:CRIS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Curis alerts:Sign Up Key Stats Today's Range$1.40▼$2.1350-Day Range$1.46▼$3.5252-Week Range$1.42▼$17.49Volume290,334 shsAverage Volume59,981 shsMarket Capitalization$12.36 millionP/E RatioN/ADividend YieldN/APrice Target$21.00Consensus RatingBuy Company OverviewCuris, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; CA-170, an oral, small molecule antagonist designated as CA-170 that selectively targets PD-L1 and VISTA; and CA-327, an oral, small molecule, TIM3/PD-L1, which is a molecule antagonist of PD-L1 and TIM3. It has collaboration agreement with Genentech Inc., or Genentech and F. Hoffmann-La Roche Ltd, or Roche, for the commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway antagonist for the treatment of advanced basal cell carcinoma, or BCC; Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology; and also licensed four programs under the Aurigene collaboration, including emavusertib. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.Read More… Remove Ads Curis Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks50th Percentile Overall ScoreCRIS MarketRank™: Curis scored higher than 50% of companies evaluated by MarketBeat, and ranked 567th out of 930 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingCuris has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageCuris has only been the subject of 1 research reports in the past 90 days.Read more about Curis' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Curis are expected to grow in the coming year, from ($7.12) to ($3.49) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Curis is -0.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Curis is -0.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCuris has a P/B Ratio of 0.44. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Curis' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.93% of the float of Curis has been sold short.Short Interest Ratio / Days to CoverCuris has a short interest ratio ("days to cover") of 1.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Curis has recently increased by 1.19%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCuris does not currently pay a dividend.Dividend GrowthCuris does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted1.93% of the float of Curis has been sold short.Short Interest Ratio / Days to CoverCuris has a short interest ratio ("days to cover") of 1.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Curis has recently increased by 1.19%, indicating that investor sentiment is decreasing. News and Social Media2.6 / 5News Sentiment0.68 News SentimentCuris has a news sentiment score of 0.68. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 20 news articles for Curis this week, compared to 1 article on an average week.MarketBeat Follows4 people have added Curis to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Curis insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.70% of the stock of Curis is held by insiders.Percentage Held by InstitutionsOnly 29.97% of the stock of Curis is held by institutions.Read more about Curis' insider trading history. Receive CRIS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Curis and its competitors with MarketBeat's FREE daily newsletter. Email Address CRIS Stock News HeadlinesCuris Stock Price, Quotes and ForecastsApril 1 at 3:12 PM | benzinga.comCuris price target lowered to $16 from $20 at H.C. WainwrightApril 1 at 3:12 PM | markets.businessinsider.comTrump… a socialist? Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.April 1, 2025 | Porter & Company (Ad)Curis, Inc. (NASDAQ:CRIS) Just Reported Full-Year Earnings And Analysts Are Lifting Their EstimatesApril 1 at 10:11 AM | finance.yahoo.comCuris, Inc. (NASDAQ:CRIS) Q4 2024 Earnings Call TranscriptApril 1 at 10:11 AM | msn.comCuris stock plunges to 52-week low at $1.97 amid market challengesApril 1 at 9:42 AM | investing.comCuris, Inc.: Curis Provides Fourth Quarter 2024 Business UpdateApril 1 at 5:11 AM | finanznachrichten.deCuris’s Promising Clinical Developments and Strategic Path to Accelerated Approval Boost Buy RatingApril 1 at 4:11 AM | tipranks.comSee More Headlines CRIS Stock Analysis - Frequently Asked Questions How have CRIS shares performed this year? Curis' stock was trading at $3.06 on January 1st, 2025. Since then, CRIS stock has decreased by 52.3% and is now trading at $1.46. View the best growth stocks for 2025 here. How were Curis' earnings last quarter? Curis, Inc. (NASDAQ:CRIS) issued its quarterly earnings results on Monday, March, 31st. The biotechnology company reported ($1.25) EPS for the quarter, beating analysts' consensus estimates of ($1.36) by $0.11. The biotechnology company had revenue of $2.70 million for the quarter, compared to analysts' expectations of $2.04 million. Curis had a negative net margin of 443.35% and a negative trailing twelve-month return on equity of 923.37%. When did Curis' stock split? Curis shares reverse split before market open on Friday, September 29th 2023. The 1-20 reverse split was announced on Friday, September 29th 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, September 29th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. How do I buy shares of Curis? Shares of CRIS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Curis own? Based on aggregate information from My MarketBeat watchlists, some other companies that Curis investors own include Micron Technology (MU), Tesla (TSLA), Meta Platforms (META), NVIDIA (NVDA), NIO (NIO), Sorrento Therapeutics (SRNE). Company Calendar Last Earnings8/01/2024Today4/01/2025Next Earnings (Estimated)4/03/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryBiotechnology Current SymbolNASDAQ:CRIS CIK1108205 Webwww.curis.com Phone(617) 503-6500Fax617-503-6501Employees60Year Founded2000Price Target and Rating Average Stock Price Target$21.00 High Stock Price Target$26.00 Low Stock Price Target$16.00 Potential Upside/Downside+1,100.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($7.81) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-47,410,000.00 Net Margins-443.35% Pretax Margin-443.35% Return on Equity-923.37% Return on Assets-78.35% Debt Debt-to-Equity RatioN/A Current Ratio1.22 Quick Ratio1.22 Sales & Book Value Annual Sales$10.26 million Price / Sales1.44 Cash FlowN/A Price / Cash FlowN/A Book Value$3.34 per share Price / Book0.52Miscellaneous Outstanding Shares8,467,000Free Float7,984,000Market Cap$14.82 million OptionableNo Data Beta3.49 Social Links 2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report This page (NASDAQ:CRIS) was last updated on 4/1/2025 by MarketBeat.com Staff From Our PartnersA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredTrump’s Secret WeaponHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsMusk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to h...InvestorPlace | SponsoredRetirement Nightmare? It’s Already Happening.The market is on edge. Every day, another company slashes its dividend, leaving investors scrambling. Intel...Investors Alley | SponsoredNew “Trump” currency proposed in DCA former U.S. Presidential Advisor has come forward with a stern warning to investors: “Get out of tech, no...Paradigm Press | SponsoredBrace Yourself for Jeff Bezos’ “Amazon Helios”Jeff Bezos quietly backing world-changing tech (not AI) The Amazon founder is quietly advancing a radical t...Stansberry Research | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Curis, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Curis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.